Publications

Detailed Information

Neutrophil to lymphocyte ratio for preoperative diagnosis of uterine sarcomas: A case-matched comparison

DC Field Value Language
dc.contributor.authorKim, H. S.-
dc.contributor.authorHan, K. H.-
dc.contributor.authorChung, H. H.-
dc.contributor.authorKim, J. W.-
dc.contributor.authorSong, Y. S.-
dc.contributor.authorKang, S. B.-
dc.contributor.authorPark, N. H.-
dc.date.accessioned2012-06-05T01:19:43Z-
dc.date.available2012-06-05T01:19:43Z-
dc.date.issued2010-07-
dc.identifier.citationEJSO; Vol.36 7; 691-698ko_KR
dc.identifier.issn0748-7983-
dc.identifier.urihttps://hdl.handle.net/10371/76827-
dc.description.abstractBackground: Uterine sarcomas are rare among all uterine malignancies, and frequently misdiagnosed as benign uterine diseases such as leiomyoma and adenomyosis because of lack of feasible tools for the preoperative diagnosis. Although some studies have suggested the role of serum CA-125 levels for the preoperative diagnosis, the efficacy is controversial. Since malignancy is known to be associated with systemic inflammation which leads to hematological alteration, we compared the efficacy for the preoperative diagnosis of uterine sarcomas between the neutrophil to lymphocyte ratio (NLR) and serum CA-125 levels using a case-match comparison. Methods: From November 2004 to December 2008, 55 patients with carcinosarcoma (n = 21), leiomyosarcoma (n = 20) and endometrial stromal sarcoma (n = 14) were matched to 330 patients with leiomyoma (n = 165) and adenomyosis (n = 165) in terms of age at diagnosis, body mass index and uterine volume. Results: The receiver operating characteristic curve showed the best cut-off values of the NLR (>= 2.12) and serum CA-125 levels (>= 27.5 U/ml) for the preoperative diagnosis of uterine sarcomas, demonstrating that the NLR was more powerful for the preoperative diagnosis of uterine sarcomas than serum CA-125 levels (sensitivity, 74.5% vs. 52.3%; specificity, 70.3% vs. 50.5%; positive predictive value, 29.5% vs. 15.1%; negative predictive value, 94.3% vs. 86.5%; accuracy, 60.6% vs. 49.6%; p<0.05). Furthermore, the NLR reflected recurrence and progression more accurately than serum CA-125 levels in patients with uterine sarcomas. Conclusions: These findings suggest that the NLR may be more useful than serum CA-125 levels as a cost-effective tool for the preoperative diagnosis in patients with uterine sarcomas. (C) 2010 Elsevier Ltd. All rights reserved.ko_KR
dc.language.isoenko_KR
dc.publisherELSEVIER SCI LTDko_KR
dc.subjectNeutrophil to lymphocyte ratioko_KR
dc.subjectLeiomyomako_KR
dc.subjectAdenomyosisko_KR
dc.subjectUterine sarcomasko_KR
dc.subjectSerum CA-125 levelsko_KR
dc.titleNeutrophil to lymphocyte ratio for preoperative diagnosis of uterine sarcomas: A case-matched comparisonko_KR
dc.typeArticleko_KR
dc.identifier.doi10.1016/j.ejso.2010.05.004-
dc.citation.journaltitleEJSO-
dc.description.citedreferenceD`Angelo E, 2010, GYNECOL ONCOL, V116, P131, DOI 10.1016/j.ygyno.2009.09.023-
dc.description.citedreferenceRay-Coquard I, 2009, CANCER RES, V69, P5383, DOI 10.1158/0008-5472.CAN-08-3845-
dc.description.citedreferenceMcMillan DC, 2009, CURR OPIN CLIN NUTR, V12, P223, DOI 10.1097/MCO.0b013e32832a7902-
dc.description.citedreferenceCho H, 2009, CANCER IMMUNOL IMMUN, V58, P15, DOI 10.1007/s00262-008-0516-3-
dc.description.citedreferenceShan WW, 2009, FRONT BIOSCI, V14, P4044, DOI 10.2741/3511-
dc.description.citedreferenceHoskins PJ, 2008, INT J GYNECOL CANCER, V18, P1200, DOI 10.1111/j.1525-1438.2007.01187.x-
dc.description.citedreferencePark JY, 2008, GYNECOL ONCOL, V109, P255, DOI 10.1016/j.ygyno.2008.01.030-
dc.description.citedreferenceHuang GS, 2007, GYNECOL ONCOL, V107, P513, DOI 10.1016/j.ygyno.2007.08.060-
dc.description.citedreferenceRYU HS, 2007, J GYNECOL ONCOL, V50, P1299-
dc.description.citedreferenceHerishanu Y, 2006, EUR J HAEMATOL, V76, P516, DOI 10.1111/j.1600-0609.2006.00658.x-
dc.description.citedreferenceOLIVARES M, 2006, REV MED CHILE, V122, P1289-
dc.description.citedreferenceWalsh Sr, 2005, J SURG ONCOL, V91, P181, DOI 10.1002/jso.20329-
dc.description.citedreferenceTanaka YO, 2004, J MAGN RESON IMAGING, V20, P998, DOI 10.1002/jmri.20207-
dc.description.citedreferenceLin EY, 2004, BRIT J CANCER, V90, P2053, DOI 10.1038/sj.bjc.6601705-
dc.description.citedreferenceBarba C, 2004, LANCET, V363, P157-
dc.description.citedreferenceBLAKEMORTIMER JS, 2004, BREAST J, V10, P195-
dc.description.citedreferenceBROOKS SE, 2004, GYNECOL ONCOL, V93, P204-
dc.description.citedreferenceSagae S, 2004, ONCOLOGY-BASEL, V67, P33, DOI 10.1159/000080283-
dc.description.citedreferenceTAVASSOLI FA, 2003, PATHOLOGY GENETICS T-
dc.description.citedreferenceWang X, 2002, ACTA CYTOL, V46, P465-
dc.description.citedreferenceKawamura N, 2002, CANCER, V94, P1713, DOI 10.1002/cncr.10382-
dc.description.citedreferenceTsujimura A, 2002, INT J ONCOL, V20, P361-
dc.description.citedreferenceRuka W, 2001, ANN ONCOL, V12, P1423-
dc.description.citedreferenceJilma B, 1999, AM J RESP CRIT CARE, V159, P857-
dc.description.citedreferencedenOuden M, 1997, EUR J OBSTET GYN R B, V72, P73-
dc.description.citedreferenceNORDAL RR, 1995, ACTA ONCOL, V34, P797-
dc.description.citedreferenceDUK JM, 1994, INT J GYNECOL CANCER, V4, P156-
dc.description.citedreferenceWOLFSON AH, 1994, GYNECOL ONCOL, V52, P56-
dc.description.citedreferencePATSNER B, 1988, CANCER, V62, P1355-
dc.description.citedreferenceANTHONY HM, 1982, BRIT J CANCER, V45, P209-
dc.description.tc3-
Appears in Collections:
Files in This Item:
There are no files associated with this item.

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share